Properties (56)
Predicate | Object |
---|---|
gptkbp:instanceOf |
drug
|
gptkbp:activeDuring |
gptkb:parathyroid_hormone
|
gptkbp:administrativeDivision |
subcutaneous injection technique
|
gptkbp:applicationStatus |
covered by many insurance plans
|
gptkbp:brand |
gptkb:Natpara
|
gptkbp:clinicalTrials |
Phase 3
ongoing studies improves quality of life long-term management recommended for hypoparathyroidism |
gptkbp:community_service |
available
|
gptkbp:contraindication |
allergic reactions
hypercalcemia hypersensitivity to the drug hypocalcemia |
gptkbp:customerFeedback |
generally positive
|
gptkbp:date |
2015-01-23
|
gptkbp:dosageForm |
injectable solution
|
gptkbp:drugInterdiction |
available online
none reported subcutaneous absorption half-life of 2 hours increases bone turnover increases serum calcium specialist only |
gptkbp:formulation |
lyophilized powder
|
gptkbp:hasPopulation |
adults
pediatric patients |
gptkbp:healthcare |
available resources
important for effectiveness injection technique signs of low calcium |
https://www.w3.org/2000/01/rdf-schema#label |
Natpara
|
gptkbp:is_monitored_by |
kidney function
calcium levels |
gptkbp:launchSite |
once daily
|
gptkbp:mandates |
treatment of low calcium levels
|
gptkbp:manufacturer |
gptkb:NPS_Pharmaceuticals
|
gptkbp:marineSafety |
available for eligible patients
|
gptkbp:market |
US_market
|
gptkbp:marketSegment |
available
|
gptkbp:offers |
varies by pharmacy
|
gptkbp:packaging |
single-use vial
|
gptkbp:regulatoryCompliance |
FDA_approved
|
gptkbp:renovated |
requires sterile water
|
gptkbp:research |
supported by grants
|
gptkbp:research_areas |
hormones
|
gptkbp:researchInterest |
published in medical journals
|
gptkbp:route |
subcutaneous injection
|
gptkbp:safetyFeatures |
generally well tolerated
|
gptkbp:sideEffect |
headache
nausea injection site reactions |
gptkbp:storage |
refrigerated
|
gptkbp:triggerType |
replaces parathyroid hormone
|
gptkbp:usedFor |
hypoparathyroidism
|